

## An Integrated Approach: Bisphosphonate Management for the Treatment of Osteoporosis

The content for this continuing education supplement to *The American Journal of Managed Care* was derived from a roundtable held in Chicago in late July 2007. All faculty and participants listed, with the exception of Rebecca Jackson, MD, attended this roundtable. The section authored by Dr Jackson was contributed after the roundtable.

### ■ Faculty/Authors

#### **Gary Owens, MD (Moderator)**

President, Gary Owens Associates, PA  
Glen Mills, Pennsylvania

#### **Rebecca Jackson, MD**

Associate Dean for Clinical Research  
College of Medicine  
Professor of Medicine, Division of Endocrinology,  
Diabetes and Metabolism  
Interim Director, Ohio State University Center  
for Women's Health  
Ohio State University Medical Center  
Columbus, Ohio

#### **E. Michael Lewiecki, MD**

Osteoporosis Director  
New Mexico Clinical Research  
& Osteoporosis Center  
Clinical Assistant Professor  
University of New Mexico School of Medicine  
Albuquerque, New Mexico

### ■ Other Roundtable Participants

#### **Paul M. Hamrah, PharmD**

Director of Pharmacy  
Kaiser Permanente  
El Cajon, California

#### **Gary L. Johnson, MD, MBA**

Director, Care Management  
Group Health Cooperative  
of South Central Wisconsin  
Madison, Wisconsin

#### **Joseph M. Johnson, MD**

(Former Vice President, Medical Affairs  
at Sierra Health Services, Health Plan  
of Nevada)

#### **Kenneth L. Schaecher, MD**

Medical Director  
SelectHealth™  
Salt Lake City, Utah

■ Faculty Disclosures

These participants have declared the following affiliations with corporate organizations:

**Rebecca Jackson, MD**

*Grant/research support from:*  
Micro MRI

*Speakers' bureau or sponsored speaking events:*

- P&G
- Roche
- sanofi-aventis

**E. Michael Lewiecki, MD**

*Grant/research support from:*

- Amgen
- Eli Lilly
- GlaxoSmithKline
- Merck
- Novartis
- P&G
- Pfizer
- Roche
- sanofi-aventis
- Wyeth

*Consultant/advisory board/speakers' bureau or sponsored speaking events:*

- Amgen
- Eli Lilly
- GlaxoSmithKline
- Merck
- Novartis
- P&G
- Roche
- sanofi-aventis
- Servier
- Upsher-Smith
- Wyeth

*Direct stock/shareholdings:*

- General Electric
- P&G

*Board of directors:*

- International Society for Clinical Densitometry

**Gary Owens, MD**

*Consultant/advisory board/speakers' bureau or sponsored speaking events:*

- Collagenex
- Eli Lilly
- Novartis
- Wyeth

*Receipt of payment for involvement in the preparation of manuscript:*

- Health Insights

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

**An Integrated  
Approach:  
Bisphosphonate  
Management for  
the Treatment of  
Osteoporosis**

■ **Participant Disclosures**

The following participants have disclosed that they do not have a financial relationship with any commercial entity that may represent a conflict of interest:

**Paul M. Hamrah, PharmD**

**Gary L. Johnson, MD, MBA**

**Joseph M. Johnson, MD**

**Kenneth L. Schaecher, MD**

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

## *An Integrated Approach: Bisphosphonate Management for the Treatment of Osteoporosis*

### GOAL

To review the impact of osteoporosis, discuss some of the challenges inherent in developing an osteoporosis management policy for the bisphosphonate class of drugs, and provide recommendations for best practices and formulary considerations that help foster effective treatment management. Recommendations include a sample integrated formulary/medical policy for bisphosphonate management.

### TARGET AUDIENCE

This educational activity is intended for managed care medical directors (physicians), pharmacy directors, and other managed care stakeholders who are involved with the management of osteoporosis therapies.

### LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

- State the incidence, prevalence, and overall impact of osteoporosis on the population
- Describe effective approaches to developing integrated disease management formulary policies
- Identify general safety and efficacy considerations for the bisphosphonate class of drugs
- Recognize what factors impact the cost of osteoporosis therapy, and in particular, the cost of bisphosphonates
- Examine a sample integrated formulary/medical policy for the bisphosphonate class of drugs, specific to the treatment of osteoporosis

There is no fee to participate in this continuing education activity.

Release date: **December 1, 2007**

Expiration date: **December 31, 2009**

### SPONSORSHIP/FINANCIAL SUPPORT

This activity is jointly sponsored by Health Insights and the University of Cincinnati.

This publication is supported by an educational grant from the Alliance for Better Bone Health, a collaboration between **P&G Pharmaceuticals** and **sanofi-aventis US**.

### PHYSICIANS

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati and Health Insights. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this educational activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This material should take approximately 30 minutes to 1 hour to complete.

### PHARMACY



Health Insights is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education, ACPE #404-000-07-012-H01-P. This program has been approved for 1.0 contact hour (0.10 CEU).

### Writing/Editorial Assistance

Health Insights provided some writing and editorial assistance to the faculty/participants for this publication.

### Trade Names

Any trade names used in this supplement are for the learner's reference only; promotion of any particular product should not be inferred.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.